BioSpace News Archive

Mileutis announced that David Javier Iscovich, CEO and co-founder, will be presenting at the Stifel 2023 Jaws & Paws Conference in New York City, May 31st, 2023.

IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense® System, today announced that ProSense was recently installed and inaugurated at Kovai Medical Center and Hospital (“KMCH”) in Coimbatore, India.

Corbus Pharmaceuticals Holdings, Inc. today announced that Yuval Cohen , Ph.D., Chief Executive Officer of Corbus, will participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference, to be held in New York, NY June 7-9, 2023.

Tavanta Therapeutics today announced that it will present new data from its metastatic prostate cancer program during the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago, as well as from its anal fissure program during the upcoming American Society of Colon and Rectal Surgeons (ASCRS) Annual Meeting being held June 3-6 in Seattle.

Mission Bio, Inc. today announced breakthrough improvements to the Tapestri® Platform and its core chemistry that enable highly confident detection of rare cells for a range of applications.

Precigen, Inc. today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to initiate a Phase 2 study of the first-in-class PRGN-2009 Off-the-Shelf (OTS) AdenoVerse™ immunotherapy in combination with pembrolizumab in patients with recurrent or metastatic cervical cancer.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company’s president and chief executive officer, will present on Wednesday, June 7, 2023 at 2:30 p.m. ET at the Jefferies 2023 Global Healthcare Conference, being held June 7-9, 2023 in New York, NY.

Abcuro, Inc. today announced completion of enrollment of the sentinel cohort of a Phase 2/3 study of ABC008 for the treatment of inclusion body myositis (IBM).

Charles River Laboratories International, Inc. and Wheeler Bio, Inc., a contract development and manufacturing organization, announced an agreement to implement RightSourceSM at Wheeler Bio’s current good manufacturing practice biologics manufacturing facility in Oklahoma City, OK.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced new analyses from the MIRROR randomized controlled trial of KRYSTEXXA® (pegloticase) injection with methotrexate show a multi-faceted impact when treating adults living with chronic gout refractory to oral therapy, or uncontrolled gout.